A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

ConditionMantle Cell Lymphoma (MCL)

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

About this trial

The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).

Eligibility criteria

Qualifiers

None

Disqualifiers

Participants known to be participating in investigational studies at the time of liso-cel infusion.

Participants treated with non-conforming CAR T-cell product.

Trial design

Treatments tested in this trial

Lisocabtagene maraleucel

Treatment groups

300 Participants

are divided into 1 treatment group

Sponsors and collaborators

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Lead sponsor

Source ClinicalTrials.gov